IMUGENE LIMITED
Imugene Ltd is a clinical stage immuno-oncology company developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumours. Imugene's platform technologies seek to harness the body's immune system against tumours, similar to synthetically manufactured monoclonal antibody and other immunotherapies.
Basic company information
Each field links to its source. Financial figures retain their reporting periods; background references are identified in the source list.
Company positioning and business
Imugene Ltd is a clinical stage immuno-oncology company developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumours. Imugene's platform technologies seek to harness the body's immune system against tumours, similar to synthetically manufactured monoclonal antibody and other immunotherapies. [3]
The company's product pipeline includes multiple immunotherapy B-cell vaccine candidates and an oncolytic virotherapy (CF33) aimed at treating a variety of cancers in combination with standard of care drugs and emerging immunotherapies such as CAR T's for solid tumours. [3]
Imugene is a publicly traded company, listed on the Australian Securities Exchange (ASX) under the code IMU. In December 2021 it entered the S&P/ASX 200 Index, in effect making it one of the 200 largest companies on the ASX. [3]
Background text: Wikipedia contributors, Imugene. Selected introductory paragraphs, licensed under CC BY-SA 4.0. Official filing data is cited separately.
Financial year, securities and disclosures
ASX security code: IMU. The exchange profile links to announcements and security information. [1]
History and key events
Founding / inception date recorded in Wikidata. [2]
Financial results and regulatory disclosures
No individual financial documents have been indexed yet. Open the source to consult company disclosures. [1]
Source-verified relationships
Companies in the same industry
Comparison candidates share the ASX industry group classification Pharmaceuticals, Biotechnology & Life Sciences. This does not imply ownership, partnership or trading relationships.
Related entities and concepts
Frequently asked questions
When was IMUGENE LIMITED founded?
Founded: 2012. The linked source provides the background record. [2]
Where is the headquarters of IMUGENE LIMITED?
Headquarters location: Melbourne. The linked source provides the background record. [2]
Which business sectors are recorded for IMUGENE LIMITED?
Business sectors: biotechnology. The linked source provides the background record. [2]
IMUGENE LIMITED relationship map
Select a node to inspect its relationship and source.
1 verified direct relationships. Industry peers are not relationship edges.
Sources and review dates
- Company identity and profile data ↗
- Wikidata — company background record (CC0) ↗
- Wikipedia contributors — Imugene (CC BY-SA 4.0) ↗
Reviewed 23 October 2026. Financial periods and historical event dates are shown separately. Figures reflect their stated source dates; this page is not a live quote or investment recommendation.